Journal of Radiation Research最新文献_第3页

Assessing cancer risk due to exposure to radionuclides in soil dust in mining areas of South Africa. 评估南非矿区土壤粉尘中放射性核素暴露导致的癌症风险。

IF 2 4区医学

Journal of Radiation Research Pub Date : 2025-09-23 DOI: 10.1093/jrr/rraf051

Violet Patricia Dudu, Masengo Ilunga, Dunisani Thomas Chabalala, Manny Mathuthu

{"title":"Assessing cancer risk due to exposure to radionuclides in soil dust in mining areas of South Africa.","authors":"Violet Patricia Dudu, Masengo Ilunga, Dunisani Thomas Chabalala, Manny Mathuthu","doi":"10.1093/jrr/rraf051","DOIUrl":"10.1093/jrr/rraf051","url":null,"abstract":"Despite the environmental significance of airborne particulates generated from mine tailings, there is limited information on exposure of people living in the neighbourhoods adjacent to such sites. The main objective of the study was to assess cancer risk due to enhanced radionuclides present in dust samples and to evaluate the exposure risk of populations living in three mining areas in the Free State and West Rand in South Africa. Soil and dust samples were collected between January 2016 and March 2018 in different seasons for determination of the level of naturally occurring radioactive materials in the samples. The samples were prepared and sealed for 4 weeks to attain secular equilibrium of the 238U and 232Th and their respective progenies, and thereafter analysed using gamma spectroscopy. Radiological parameters were calculated from the activity of the radionuclides to estimate exposure risk. The absorbed dose rate in air ranged from 76 to 137, 50 to 133 and 19 to 75 (nGy hr-1) for areas A, B and C, respectively. The mean excess lifetime cancer risk in all three mines was lower than the world average of 1.45 × 10-3; accordingly, the cancer risk was found to be negligible. The findings revealed that most radiological parameters were within the accepted international values; thus the soils in the areas could be considered to be safe for the humans living there.","PeriodicalId":16922,"journal":{"name":"Journal of Radiation Research","volume":" ","pages":"509-519"},"PeriodicalIF":2.0,"publicationDate":"2025-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12485230/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144992819","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A new hyaluronate gel spacer and injection technique for cervical cancer brachytherapy: a technical report. 一种新的透明质酸凝胶间隔和注射技术用于宫颈癌近距离治疗：技术报告。

IF 2 4区医学

Journal of Radiation Research Pub Date : 2025-09-17 DOI: 10.1093/jrr/rraf055

Yusaku Miyata, Etsuyo Ogo, Kenta Murotani, Kazuya Nagahiro, Kento Hoshida, Naotake Tsuda, Shin Nishio, Gaku Shioyama, Nona Fujimoto, Tetsuo Yamasaki, Ryosuke Akeda, Koichiro Muraki, Chiyoko Tsuji, Chikayuki Hattori, Shuichi Tanoue

{"title":"A new hyaluronate gel spacer and injection technique for cervical cancer brachytherapy: a technical report.","authors":"Yusaku Miyata, Etsuyo Ogo, Kenta Murotani, Kazuya Nagahiro, Kento Hoshida, Naotake Tsuda, Shin Nishio, Gaku Shioyama, Nona Fujimoto, Tetsuo Yamasaki, Ryosuke Akeda, Koichiro Muraki, Chiyoko Tsuji, Chikayuki Hattori, Shuichi Tanoue","doi":"10.1093/jrr/rraf055","DOIUrl":"https://doi.org/10.1093/jrr/rraf055","url":null,"abstract":"Spacers separating the tumor from adjacent organs help improve irradiation dose parameters. We introduce a new hyaluronate gel spacer with MEIJI (ADANT®) as an alternative to the previously used Suvenyl® and its injection technique for cervical cancer brachytherapy. Five patients with cervical cancer underwent hyaluronate gel injection (HGI) with the MEIJI hyaluronate gel in their rectovaginal and vesicovaginal septa. The minimum doses covering 90% of the high-risk clinical target volume (CTVHRD90%), the most exposed 2 cc (D2cc) of organs at risk per session, as well as the total doses for combined external beam radiotherapy (with a central shield) and brachytherapy, were assessed. The median CTVHRD90% was 9.3 (range, 6.4-9.7) Gy per session and 92.2 Gy in the equivalent dose in 2 Gy fractions (EQD2) (80.3-93.3 Gy-EQD2) overall. The median rectum D2cc was 2.9 (1.8-5.0) Gy per session and 45.4 (43.4-57.1) Gy-EQD2 overall. The median D2cc of the bladder (bladder D2cc) was 4.8 (2.4-6.5) Gy per session and 64.6 (62.3-69.6) Gy-EQD2 overall. The MEIJI spacer disappeared within 3 or 7 days with no adverse events associated with HGI or deterioration of the patients' quality of life. MEIJI HGI facilitates a sufficient CTVHRD90% while keeping the rectal and bladder D2cc within dose constraints, even when the rectum and bladder are in close proximity to the CTVHR. In conclusion, the MEIJI spacer may help appropriately meet dose constraints, thereby potentially contributing to improving local control and/or reducing adverse events for patients receiving radiotherapy for cervical cancer.","PeriodicalId":16922,"journal":{"name":"Journal of Radiation Research","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2025-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145092090","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Performance evaluation of ESR dosimeters under proton beam FLASH irradiation conditions. 质子束FLASH辐照条件下ESR剂量计的性能评价。

IF 2 4区医学

Journal of Radiation Research Pub Date : 2025-09-17 DOI: 10.1093/jrr/rraf054

Jun Kumagai, Hiromitsu Iwata, Kenji Komaguchi, Chihiro Omachi, Toshiyuki Toshito, Masumi Umezawa, Masashi Yamada, Takashi Kondo

{"title":"Performance evaluation of ESR dosimeters under proton beam FLASH irradiation conditions.","authors":"Jun Kumagai, Hiromitsu Iwata, Kenji Komaguchi, Chihiro Omachi, Toshiyuki Toshito, Masumi Umezawa, Masashi Yamada, Takashi Kondo","doi":"10.1093/jrr/rraf054","DOIUrl":"https://doi.org/10.1093/jrr/rraf054","url":null,"abstract":"Two chemical dosimeters, lithium formate monohydride (LFM) and L-alanine (ALA), were first evaluated under ultra-high dose rate (UHDR) proton irradiation conditions, known as 'FLASH', which has the potential to reduce the impact on normal tissue while effectively killing tumors, using electron spin resonance (ESR) spectroscopy. Both ALA and LFM demonstrated a significant linear increase in ESR peaks that correlated with the physical dose when comparing conventional radiation (CONV) to UHDR radiation. The relative effectiveness (RE: the ratio of the amount of free radicals produced by each type of proton irradiation to the amount produced by 60Co γ-ray irradiation) was determined for CONV, UHDR-Plateau and UHDR-Peak, yielding RE values of 0.849, 0.731 and 0.661 for LFM and 0.834, 0.692 and 0.624 for ALA, respectively. The decrease in RE values was likely due to the combination of UHDR and the increase of linear energy transfer (LET) to facilitate the recombination of radicals formed within the crystal during CONV and UHDR of proton beams. When using the height of the ESR central peak as an indicator of sensitivity, LFM was assessed to be ~20% more sensitive than ALA.","PeriodicalId":16922,"journal":{"name":"Journal of Radiation Research","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2025-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145092071","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Stereotactic body radiation therapy for renal cell carcinoma: a small number of initial clinical experiences. 立体定向放射治疗肾细胞癌：少量初步临床经验。

IF 1.9 4区医学

Journal of Radiation Research Pub Date : 2025-07-22 DOI: 10.1093/jrr/rraf028

Takahiro Aoyama, Yutaro Koide, Hidetoshi Shimizu, Tomoki Kitagawa, Tohru Iwata, Shingo Hashimoto, Hiroyuki Tachibana, Takeshi Kodaira

{"title":"Stereotactic body radiation therapy for renal cell carcinoma: a small number of initial clinical experiences.","authors":"Takahiro Aoyama, Yutaro Koide, Hidetoshi Shimizu, Tomoki Kitagawa, Tohru Iwata, Shingo Hashimoto, Hiroyuki Tachibana, Takeshi Kodaira","doi":"10.1093/jrr/rraf028","DOIUrl":"10.1093/jrr/rraf028","url":null,"abstract":"Stereotactic body radiation therapy (SBRT) has emerged as a promising and minimally invasive treatment option for patients with renal cell carcinoma (RCC). This study presents our initial clinical experiences with treatments following our center's protocol, which was formulated based on both national and international evidence. Six patients who had undergone renal SBRT at our center from January 2021 to December 2023 were included. Treatment planning used computed tomography (CT) and magnetic resonance imaging, with respiratory management conducted through breath-hold or free-breathing techniques. The prescribed dose was primarily 48 Gy in three fractions, with increased fractionations when dose constraints were challenging to achieve. Dose constraints were met for all patients, and treatment planning adhered to protocol guidelines. After the confirmation of cone-beam CT (CBCT) images by physicians, radiation was delivered. Five out of six patients completed the planned treatment, whereas one discontinued the treatment midway (the causal relationship to radiation therapy was unclear). Dose-volume histogram analysis revealed that doses to organs at risk depended on the position and size of the planning target volume but remained within acceptable limits for all cases. The intrafractional patient motion was 2.7 mm, as calculated from the pre- and post-CBCT images, confirming the appropriateness of a 3-mm setup margin. Although this study provides initial insights, further clinical trials are warranted to establish standardized protocols and optimize treatment strategies for RCC. In the future, it is also necessary to generate evidence that is tailored to the current situation in Japan.","PeriodicalId":16922,"journal":{"name":"Journal of Radiation Research","volume":" ","pages":"429-435"},"PeriodicalIF":1.9,"publicationDate":"2025-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12283516/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144216201","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Occupational radiation exposure of therapists in clinical use of spot scanning proton-carbon ion synchrotron systems. 临床使用点扫描质子-碳离子同步加速器系统时治疗师的职业辐射暴露。

IF 1.9 4区医学

Journal of Radiation Research Pub Date : 2025-07-22 DOI: 10.1093/jrr/rraf023

Zhulei Liu, Dan You, Dan Zhou, Ruirui Bu, Yao Li, Xiaowa Wang

{"title":"Occupational radiation exposure of therapists in clinical use of spot scanning proton-carbon ion synchrotron systems.","authors":"Zhulei Liu, Dan You, Dan Zhou, Ruirui Bu, Yao Li, Xiaowa Wang","doi":"10.1093/jrr/rraf023","DOIUrl":"10.1093/jrr/rraf023","url":null,"abstract":"This study addresses the escalating radiation safety concerns among medical professionals due to the rising application of proton and carbon ion radiotherapy. It evaluates the occupational radiation exposure faced by therapists when utilizing the Siemens IONTRIS Proton-Carbon Ion System. Through random sampling of 80 patients treated between January and June 2024, we recorded particle types and counts and measured dose rates using a photon/neutron radiation dose meter. Notably, 1 min post-treatment, the dose rate peaked at 16.00 μSv/h near the tumor's skin surface, showing a significant correlation with particle count. The therapist's standing position and the surfaces of the range shifter and ripple filter registered average dose rates of 1.25 μSv/h and 3.63 μSv/h, 0.33 μSv/h, respectively. Other points averaged 0.08 μSv/h, with no neutron detection. The study concludes that the annual average occupational exposure for therapists, at ~300 μSv, is significantly below the International Commission on Radiological Protection's recommended dose equivalent limit, confirming the safety of the Siemens IONTRIS device in clinical settings.","PeriodicalId":16922,"journal":{"name":"Journal of Radiation Research","volume":" ","pages":"365-371"},"PeriodicalIF":1.9,"publicationDate":"2025-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12283513/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144187236","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Radiotherapy for human T-cell leukemia virus type 1-associated adult T-cell leukemia/lymphoma. 人类t细胞白血病病毒1型相关成人t细胞白血病/淋巴瘤的放疗

IF 1.9 4区医学

Journal of Radiation Research Pub Date : 2025-07-22 DOI: 10.1093/jrr/rraf036

Kohei Tokuyama, Takayoshi Itaya, Ayaka Hara, Motoko Tanabe, Shoko Takata, Takashige Kiyota, Tomoko Yamate, Yutaka Hatano, Masao Ogata, Kuniko Takano, Yoshiki Asayama

{"title":"Radiotherapy for human T-cell leukemia virus type 1-associated adult T-cell leukemia/lymphoma.","authors":"Kohei Tokuyama, Takayoshi Itaya, Ayaka Hara, Motoko Tanabe, Shoko Takata, Takashige Kiyota, Tomoko Yamate, Yutaka Hatano, Masao Ogata, Kuniko Takano, Yoshiki Asayama","doi":"10.1093/jrr/rraf036","DOIUrl":"10.1093/jrr/rraf036","url":null,"abstract":"Adult T-cell lymphoma/leukemia (ATL) is an aggressively malignant peripheral T-cell neoplasm. Only a few studies have reported the use of radiotherapy (RT) for ATL. Therefore, the aim of this study was to clarify the efficacy of RT for ATL. We retrospectively reviewed 90 courses of RT administered to 19 consecutive ATL patients between 2008 and 2023. The subtypes included lymphoma (n = 8), acute (n = 7), smoldering (n = 3) and unknown (n = 1). Ninety lesions (cutaneous = 72, extranodal = 10, nodal = 8) were treated at a mean dose of 39.1 Gy/3.2 Gy (range, 24-60 Gy). Administration of RT for ATL lesions resulted in a combined complete response and partial response rate of 92%. At a mean of 47.5 months of follow-up (range, 0-102 months), local recurrence was not observed in 98.9% of the courses. A treatment response in terms of clinical symptoms was observed in 92% of the courses. The median survival time was 918 days. No acute grade ≥3 toxicity or any late toxicity was noted. In conclusion, RT was confirmed to be effective and safe for the treatment of local ATL lesions.","PeriodicalId":16922,"journal":{"name":"Journal of Radiation Research","volume":" ","pages":"423-428"},"PeriodicalIF":1.9,"publicationDate":"2025-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12283514/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144618644","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Radiotherapy treatment planning for esophageal cancer: JASTRO guidelines 2024 for radiotherapy treatment planning. 食管癌放疗治疗计划：JASTRO指南2024放疗治疗计划。

IF 1.9 4区医学

Journal of Radiation Research Pub Date : 2025-07-22 DOI: 10.1093/jrr/rraf029

Keiichi Jingu, Keiji Nihei, Yoshinori Ito, Masahiko Okamoto, Hiroshi Doi, Hirofumi Ogawa, Masakatsu Onozawa, Terufumi Kawamoto, Norio Katoh, Atsuya Takeda, Hirokazu Makishima, Hiroshi Mayahara, Hideya Yamazaki, Keiko Nemoto Murofushi, Kayoko Tsujino, Hiroshi Igaki, Takashi Uno

{"title":"Radiotherapy treatment planning for esophageal cancer: JASTRO guidelines 2024 for radiotherapy treatment planning.","authors":"Keiichi Jingu, Keiji Nihei, Yoshinori Ito, Masahiko Okamoto, Hiroshi Doi, Hirofumi Ogawa, Masakatsu Onozawa, Terufumi Kawamoto, Norio Katoh, Atsuya Takeda, Hirokazu Makishima, Hiroshi Mayahara, Hideya Yamazaki, Keiko Nemoto Murofushi, Kayoko Tsujino, Hiroshi Igaki, Takashi Uno","doi":"10.1093/jrr/rraf029","DOIUrl":"10.1093/jrr/rraf029","url":null,"abstract":"The Japanese Society for Radiation Oncology (JASTRO) Guidelines for Radiotherapy Treatment Planning have been revised every four years to incorporate the latest findings since the publication of the first edition in 2004. This is a review which presents the 2024 JASTRO Guidelines for radiotherapy treatment planning for esophageal cancer in English. Regarding the treatment of esophageal cancer, various new findings have emerged over the past 4 years, leading to significant updates in the 2020 edition, particularly in the following six areas: (i) additional details on indications for superficial cancer, (ii) inclusion of clinical trial results (JCOG1109) for neoadjuvant chemotherapy and chemoradiotherapy in locally advanced cases in Japan, (iii) updated references on prophylactic lymph node irradiation, (iv) updates on IMRT, (v) revisions in accordance with the 5th edition of the Esophageal Cancer Treatment Guidelines, and (vi) additions of FOLFOX to concurrent chemotherapy regimens.","PeriodicalId":16922,"journal":{"name":"Journal of Radiation Research","volume":" ","pages":"354-364"},"PeriodicalIF":1.9,"publicationDate":"2025-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12283517/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144216200","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Release of HMGB1 from human-derived cancer and normal cells by internal targeted radiotherapy with 131I-meta-iodobenzylguanidine. 131i -间碘苄基胍内靶向放疗对人源癌和正常细胞HMGB1释放的影响

IF 1.9 4区医学

Journal of Radiation Research Pub Date : 2025-07-22 DOI: 10.1093/jrr/rraf034

Kakeru Sato, Ririka Handa, Jianwei Yao, Yuka Hirayama, Yuna Hamada, Jundai Yamagata, Taiga Watanabe, Asuka Mizutani, Hiroshi Wakabayashi, Masato Kobayashi, Ryuichi Nishii, Keiichi Kawai

{"title":"Release of HMGB1 from human-derived cancer and normal cells by internal targeted radiotherapy with 131I-meta-iodobenzylguanidine.","authors":"Kakeru Sato, Ririka Handa, Jianwei Yao, Yuka Hirayama, Yuna Hamada, Jundai Yamagata, Taiga Watanabe, Asuka Mizutani, Hiroshi Wakabayashi, Masato Kobayashi, Ryuichi Nishii, Keiichi Kawai","doi":"10.1093/jrr/rraf034","DOIUrl":"10.1093/jrr/rraf034","url":null,"abstract":"The rare abscopal effect in radiotherapy is thought to result from immune-activating damage-associated molecular patterns, such as high mobility group box-1 protein (HMGB1), released from cancer cells. While external irradiation of cancer cells increases HMGB1 release, it remains unclear whether internal radiotherapy with 131I-meta-iodobenzylguanidine (131I-MIBG) induces similar effects. This study aimed to determine if HMGB1 is released from human-derived cancer and normal cells after 131I-MIBG administration. The number of cells, extracellular lactate dehydrogenase (LDH) and HMGB1 were measured in H441 and human keratinocyte cell line (HaCaT) at 1 day after 2- and 10-Gy X-ray irradiation. Accumulations of 131I-MIBG in SH-SY5Y and HaCaT were measured at 60 min after 131I-MIBG (0.37, 1.85 and 3.7 MBq/well) administration. The number of cells, extracellular LDH and HMGB1 were measured at 1 day after 131I-MIBG treatment. Results: The total number of cells decreased in both H441 and HaCaT at 1 day after 10-Gy X-ray irradiation. Extracellular LDH and HMGB1 from H441 after 10-Gy X-ray irradiation were significantly increased, while no increase was observed in HaCaT after 2- and 10-Gy X-ray irradiation. After 1.85 MBq (~4-Gy by converting of PHITS simulation) and 3.7 MBq 131I-MIBG (8-Gy) administrations, the total number of cells decreased in both SH-SY5Y and HaCaT at 1 day after 131I-MIBG administration. Extracellular LDH and HMGB1 were both significantly increased in SH-SY5Y, but only extracellular LDH was significantly increased in HaCaT. HMGB1 was released from neuroblastoma cells but not from normal cells after 131I-MIBG administration. A combination of 131I-MIBG and immunotherapy may be feasible.","PeriodicalId":16922,"journal":{"name":"Journal of Radiation Research","volume":" ","pages":"385-395"},"PeriodicalIF":1.9,"publicationDate":"2025-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12283520/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144528502","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prospective study of a rotating gantry with scanning beams of carbon-ion radiotherapy for choroidal malignant melanoma. 旋转龙门碳离子放射治疗脉络膜恶性黑色素瘤的前瞻性研究。

IF 1.9 4区医学

Journal of Radiation Research Pub Date : 2025-07-22 DOI: 10.1093/jrr/rraf030

Masaru Wakatsuki, Hirokazu Makishima, Shuri Aoki, Nao Kobayashi, Hiroshi Tsuji, Hitoshi Ishikawa, Shigeru Yamada, Atsushi Mizota

{"title":"Prospective study of a rotating gantry with scanning beams of carbon-ion radiotherapy for choroidal malignant melanoma.","authors":"Masaru Wakatsuki, Hirokazu Makishima, Shuri Aoki, Nao Kobayashi, Hiroshi Tsuji, Hitoshi Ishikawa, Shigeru Yamada, Atsushi Mizota","doi":"10.1093/jrr/rraf030","DOIUrl":"10.1093/jrr/rraf030","url":null,"abstract":"To evaluate the safety of a rotating gantry with scanning beams of carbon-ion radiotherapy (C-ion RT) for choroidal malignant melanoma. A prospective study of C-ion RT using a rotating gantry with scanning beams for choroidal malignant melanoma was initiated at the National Institute for Quantum Science and Technology, QST Hospital in March 2018. The inclusion criteria were as follows: (i) clinically diagnosed ocular/choroidal malignant melanoma; (ii) tumor measurable by imaging tests; (iii) score of 0-2 on the Eastern Cooperative Oncology Group Performance Status scale and (iv) ability to provide consent for treatment. All patients received 68 Gy in four fractions of C-ion RT by a rotating gantry with scanning beams. Between April 2018 and July 2019, 21 patients were enrolled and underwent C-ion RT as planned. All 21 patients completed the treatment schedule and the 3-year follow-up period. The median duration of follow-up was 43 months (range, 35.2-54.6 months). Regarding late normal tissue responses, three of the 21 patients developed grade 2 neovascular glaucoma; however, no other late grade ≥2 acute toxicities were observed. During the 3-year study period, all 21 patients survived with no local recurrence; none of the patients underwent enucleation. Three cases showed liver metastasis. The 3-year local control, overall survival and eye-retention rates were all 100%. The results of this prospective study confirmed that the effectiveness and safety of this method are equivalent to those of conventional passive irradiation methods, although the number of cases was small. The results of this prospective study confirmed that the effectiveness and safety of this method are equivalent to those of conventional passive irradiation methods, although the number of cases was small.","PeriodicalId":16922,"journal":{"name":"Journal of Radiation Research","volume":" ","pages":"408-414"},"PeriodicalIF":1.9,"publicationDate":"2025-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12283515/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144266471","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Retraction of: Fractionated irradiation-induced EMT-like phenotype conferred radioresistance in esophageal squamous cell carcinoma. 分次辐照诱导的emt样表型与食管鳞状细胞癌的放射耐药有关。

IF 1.9 4区医学

Journal of Radiation Research Pub Date : 2025-07-22 DOI: 10.1093/jrr/rraf033

引用次数: 0